Rescuing SLAMF3 Expression Restores Sorafenib Response in Hepatocellular Carcinoma Cells through the Induction of Mesenchymal-to-Epithelial Transition

SIMPLE SUMMARY: Sorafenib is a treatment for advanced HCC which demonstrated a poor objective response rate due to important induction of resistance. We demonstrated that induction of acquired-resistance to sorafenib in Huh-7 cell line leads to the loss of SLAMF3 expression, a tumor suppressor recep...

Descripción completa

Detalles Bibliográficos
Autores principales: Fouquet, Grégory, Marié, Constance, Collet, Louison, Vilpoux, Catherine, Ouled-Haddou, Hakim, Nguyen-Khac, Eric, Bayry, Jagadeesh, Naassila, Mickaël, Marcq, Ingrid, Bouhlal, Hicham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869973/
https://www.ncbi.nlm.nih.gov/pubmed/35205659
http://dx.doi.org/10.3390/cancers14040910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869973/
https://www.ncbi.nlm.nih.gov/pubmed/35205659
http://dx.doi.org/10.3390/cancers14040910

Ejemplares similares